Patient Home Monitoring

PHM-X

Analysis and Opinions about PHM-X

Signal
Opinion
Expert
BUY
BUY
April 21, 2014

Has been adding to his position. They had growing pains. They staffed up and will take better care of their investor relations. This is a hot space right now. Thinks they will grind out some pretty good numbers.

Show full opinionHide full opinion

Has been adding to his position. They had growing pains. They staffed up and will take better care of their investor relations. This is a hot space right now. Thinks they will grind out some pretty good numbers.

BUY
BUY
April 21, 2014

(Market Call Minute.) Have executed well on their acquisitions and you are going to start to see those synergies drop to the bottom line.

Show full opinionHide full opinion

(Market Call Minute.) Have executed well on their acquisitions and you are going to start to see those synergies drop to the bottom line.

COMMENT
COMMENT
April 16, 2014

Essentially they provide services related to healthcare, particularly with regards to monitoring a drug called Coumadin. Has also been a consolidator by acquiring businesses that have relatively attractive valuations. The idea is that they can cross sell products and services that they have.

Show full opinionHide full opinion

Essentially they provide services related to healthcare, particularly with regards to monitoring a drug called Coumadin. Has also been a consolidator by acquiring businesses that have relatively attractive valuations. The idea is that they can cross sell products and services that they have.

BUY
BUY
February 25, 2014

Likes it and the strategy as well as the management team. They buy small US based home monitoring companies and cross sell into that database. They fly under Obamacare’s radar. He would buy more here.

Show full opinionHide full opinion

Likes it and the strategy as well as the management team. They buy small US based home monitoring companies and cross sell into that database. They fly under Obamacare’s radar. He would buy more here.

COMMENT
COMMENT
January 15, 2014

A smaller cap companies where it is too hard to tell because of the ebb and flow. You have to really look at the business and this is a great business. They are basically monitoring people in their home for a number of different things. Just recently announced a couple of acquisitions that are expanding their revenue and earnings. Expect they will continue on this acquisition trail. If this consolidated a bit, you should add to your position.

Show full opinionHide full opinion

A smaller cap companies where it is too hard to tell because of the ebb and flow. You have to really look at the business and this is a great business. They are basically monitoring people in their home for a number of different things. Just recently announced a couple of acquisitions that are expanding their revenue and earnings. Expect they will continue on this acquisition trail. If this consolidated a bit, you should add to your position.

PAST TOP PICK
PAST TOP PICK
December 16, 2013

(A Top Pick Sept 18/13. Up 5.77%.) Have a monitoring of a heart drug in the US called Cuberton (?) and instead of doing it in a hospital once a month, the patient is able to do it in their home on a weekly basis. Saves Medicare a substantial amount of money. This is their bread and butter business and is adding on various types of business on top of that.

Show full opinionHide full opinion

(A Top Pick Sept 18/13. Up 5.77%.) Have a monitoring of a heart drug in the US called Cuberton (?) and instead of doing it in a hospital once a month, the patient is able to do it in their home on a weekly basis. Saves Medicare a substantial amount of money. This is their bread and butter business and is adding on various types of business on top of that.

BUY
BUY
December 10, 2013

Home monitoring for patients in the US which is a growth industry. 10,000 people turn 65 in the US every day. Government has a problem. There is a lot of demand for health dollars and there are not a lot of dollars coming in. Government is pushing policies that will benefit patient home strategy, i.e. patients taking care of themselves. This company cobbled together a group of smaller businesses that some way or other, are in the home patient monitoring business and the idea is to get revenue synergies by cross selling. They are in the middle of a raise right now, and once that closes he expects to see the stock to go back North of $0.30. He could see this at $0.40-$0.45 in a year.

Show full opinionHide full opinion

Home monitoring for patients in the US which is a growth industry. 10,000 people turn 65 in the US every day. Government has a problem. There is a lot of demand for health dollars and there are not a lot of dollars coming in. Government is pushing policies that will benefit patient home strategy, i.e. patients taking care of themselves. This company cobbled together a group of smaller businesses that some way or other, are in the home patient monitoring business and the idea is to get revenue synergies by cross selling. They are in the middle of a raise right now, and once that closes he expects to see the stock to go back North of $0.30. He could see this at $0.40-$0.45 in a year.

COMMENT
COMMENT
September 30, 2013

Just started to take a look at it. It is very interesting. An area where there is tremendous need. Address parents you want to make sure are looked after if they stay in their home and get alerts when things are askew. He needs to meet the management team and to see more strength on the balance sheet for acquisitions.

Show full opinionHide full opinion

Just started to take a look at it. It is very interesting. An area where there is tremendous need. Address parents you want to make sure are looked after if they stay in their home and get alerts when things are askew. He needs to meet the management team and to see more strength on the balance sheet for acquisitions.

TOP PICK
TOP PICK
September 18, 2013

400,000 patients. Have a device that allows blood work and testing in their own homes. They are tapping into 10% of the patients that qualify for this. Sees cross selling of other products going forward.

Show full opinionHide full opinion

400,000 patients. Have a device that allows blood work and testing in their own homes. They are tapping into 10% of the patients that qualify for this. Sees cross selling of other products going forward.

TOP PICK
TOP PICK
September 6, 2013

A home monitoring of people with an illness in the US. This is a big industry because of 3 things. 1.) Fiscal health of governments is very poor. 2.) Demographics of 10,000 Americans turning 65 every day, which means they go into Medicare and the government has to pay their health bills. 3.) Technology is coming up with ways for people to stay home and keep an eye on their own house so they don’t have a stay in hospital for a long time.

Show full opinionHide full opinion

A home monitoring of people with an illness in the US. This is a big industry because of 3 things. 1.) Fiscal health of governments is very poor. 2.) Demographics of 10,000 Americans turning 65 every day, which means they go into Medicare and the government has to pay their health bills. 3.) Technology is coming up with ways for people to stay home and keep an eye on their own house so they don’t have a stay in hospital for a long time.

Showing 166 to 175 of 175 entries